Phlebitis News and Research

RSS

Association between SARS-CoV-2 infection and several key respiratory and non-respiratory complications

Researchers assessed the intensity of association between SARS-CoV-2 infection and risks of various respiratory and non-respiratory complications.

9 Feb 2022

Genetically predicted COVID-19 linked to blood clots, thrombophlebitis and circulatory diseases

Research led by Queen Mary University of London associates genetically determined COVID-19 susceptibility with increased blood clot events in leg and lungs, thrombophlebitis and circulatory diseases.

8 Sep 2021

Robot that can draw blood in humans

Soon, robots can take blood samples that can benefit both patients and healthcare workers, thanks to a new blood-sampling robot. A few years back, it was developed but was only tested on plastic arms. Now, the robot has been successfully trialed on live humans.

9 Feb 2020

New blood-sampling robot performs as well or better than people

In the future, robots could take blood samples, benefiting patients and healthcare workers alike.

6 Feb 2020

Air pollution could be associated with more health problems than previously thought

A new study reveals that several more problems could be associated with air pollution than previously believed. The problems associated with air pollution are not just limited to the respiratory ailments but go deeper say researchers from Harvard University and others.

28 Nov 2019

Study shows cardiovascular problems are more common in uterine cancer survivors

A new study in the Journal of the National Cancer Institute indicates that survivors of uterine cancer are more likely to experience cardiovascular problems years after treatment.

8 May 2018

Study suggests using hypertonic saline infusions via peripheral catheter may help avoid complications

Current recommendations that a central catheter is required for continuous intravenous infusion of 3 percent sodium chloride solution should be re-evaluated, according to a study in the American Journal of Critical Care.

4 Jan 2017

Naturally occurring clay exhibits potent antibacterial activity against ESKAPE pathogens

Naturally occurring clay from British Columbia, Canada -- long used by the region's Heiltsuk First Nation for its healing potential -- exhibits potent antibacterial activity against multidrug-resistant pathogens, according to new research from the University of British Columbia.

27 Jan 2016

Rituximab drug may be safe, effective for immunoglobulin G4-related disease treatment

Rituximab (Rituxan) — a drug commonly used rheumatoid arthritis, granulomatosis with polyangiitis (formerly Wegener's), and certain types of cancers — may be a safe and effective treatment for immunoglobulin G4-related disease (commonly called IgG4-RD), according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Intravenous catheter replacement: an interview with Claire Rickard

Peripheral intravenous catheters (“IV drips”) are small plastic tubes inserted into veins, most frequently in the hand or arm.

30 Oct 2012

Changing iv catheters only when necessary 'could benefit millions'

Peripheral intravenous catheters need be removed only when clinically indicated, rather than every 72 to 96 hours, as is currently recommended, conclude Australian researchers in findings that could have dramatic patient and cost benefits.

21 Sep 2012

Intravenous catheter replacement should take place only when clinically necessary

New research published in the third Article in The Lancet surgery-themed issue suggests that the millions of intravenous catheters used each year can be safely changed only when clinically necessary, overturning 40 years of accepted practice involving routine replacement every 3 days.

21 Sep 2012

Three-step clinical pathway for CAP reduces length of hospital stay

A three-step pathway helps to reduce the duration of intravenous antibiotic treatment in hospitalized patients with community-acquired pneumonia, show study findings published in the Archives of Internal Medicine.

2 Jul 2012

FDA clears Teleflex’s ARROW PICC with Chloragard technology

Teleflex Incorporated announced today that in addition to broad-spectrum antimicrobial protection, the pressure-injectable ARROW PICC with Chloragard Technology provides antithrombogenic protection for at least 30 days.

22 May 2012

Peripheral IV catheter effective alternative to central lines

A new study concludes that the POWERWAND peripheral IV (PIV) catheter is an effective alternative to central lines and standard PIV's, achieving unprecedented levels of success in patients requiring longer-term IV therapy.

5 Apr 2012

Varicose veins may be a simple cosmetic issue or a serious medical problem

With spring break shorts and swimsuit season coming up, many people will soon show off their legs for the first time in months, and for some, that also means deciding what to do about unsightly varicose veins. The bulging purple or blue lines may be simply a cosmetic issue, or they could be a sign of a serious medical problem, says Mayo Clinic vascular surgeon Peter Gloviczki, M.D.

14 Mar 2012

ViroPharma's NDS for Cinryze receives Health Canada's Priority Review status

ViroPharma Incorporated today announced that Health Canada has granted the company Priority Review status for its New Drug Submission (NDS) for Cinryze (C1 inhibitor [human]).

13 Jan 2012

ViroPharma initiates Cinryze Phase 2 subcutaneous trial in patients with HAE

ViroPharma Incorporated and Halozyme Therapeutics announced today that ViroPharma has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze in combination with Halozyme's Enhanze technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme, in subjects with hereditary angioedema.

14 Sep 2011

ViroPharma receives European Centralized Marketing Authorization for Cinryze for treatment of HAE

ViroPharma Incorporated today announced that the European Commission has granted ViroPharma Centralized Marketing Authorization for Cinryze (C1 inhibitor [human]) in adults and adolescents with hereditary angioedema (HAE) for routine prevention, pre-procedure prevention and acute treatment of angioedema attacks.

16 Jun 2011

Sanofi's semuloparin Phase III study data against venous thromboembolism presented at ASCO 2011

Sanofi US announced today results of the pivotal SAVE-ONCO study which demonstrated that, in cancer patients initiating a chemotherapy regimen, investigational semuloparin significantly reduced the risk of the composite of symptomatic-deep vein thromboembolism (DVT), non-fatal pulmonary embolism (PE) or venous thromboembolism (VTE)-related death by 64%, meeting the study primary endpoint.

4 Jun 2011